Borrelia and Chlamydia Can Form Mixed Biofilms in Infected Human Skin Tissues

Our research group has recently shown that Borrelia burgdorferi, the Lyme disease bacterium, is capable of forming biofilms in Borrelia-infected human skin lesions called Borrelia lymphocytoma (BL). Biofilm structures often contain multiple organisms in a symbiotic relationship, with the goal of providing shelter from environmental stressors such as antimicrobial agents. Because multiple co-infections are common in Lyme disease, the main questions of this study were whether BL tissues contained other pathogenic species and/or whether there is any co-existence with Borrelia biofilms. Recent reports suggested Chlamydia-like organisms in ticks and Borrelia-infected human skin tissues; therefore, Chlamydia-specific polymerase chain reaction (PCR) analyses were performed in Borrelia-positive BL tissues. Analyses of the sequence of the positive PCR bands revealed that Chlamydia spp. DNAs are indeed present in these tissues, and their sequences have the best identity match to Chlamydophila pneumoniae and Chlamydia trachomatis. Fluorescent immunohistochemical and in situ hybridization methods demonstrated the presence of Chlamydia antigen and DNA in 84% of Borrelia biofilms. Confocal microscopy revealed that Chlamydia locates in the center of Borrelia biofilms, and together, they form a well-organized mixed pathogenic structure. In summary, our study is the first to show Borrelia-Chlamydia mixed biofilms in infected human skin tissues, which raises the questions of whether these human pathogens have developed a symbiotic relationship for their mutual survival.

Definition of novel electrochemotherapy parameters and validation of their in vitro and in vivo effectiveness

Electrochemotherapy (ECT) is a cancer therapy that conjugates the administration of a chemotherapy agent to the delivery of permeabilizing pulses released singularly or as bursts. This approach results in higher number of anticancer molecules delivered to their biological targets, but is also associated to undesirable side effects such as pain and muscular contractions. A new electroporator delivering train of eight biphasic pulses at the voltage of 1,300 V/cm lasting 50 + 50 µsec each, with a frequency of 1 Hz, and with 10-µsec interpulse intervals (total treatment time: 870 µsec/cm(2) of treated area) was tested in vitro on the human lung cancer cell line A549 and in vivo, both in mice xenografts and privately owned rabbits with spontaneous tumors. The tumor cell line was treated with electroporation using the new parameters, that showed improved drug efficacy in causing cell death. Mice with chemoresistant xenografts were treated as well with either the new parameters and with a previous protocol, confirming the higher tolerability and efficacy of the novel parameters. Finally, a cohort of six pet rabbits with advanced skin neoplasms were enrolled in a compassionate trial using the new parameters in adjuvant fashion. In terms of efficacy, none of the rabbits experienced tumor recurrence, showing minimal discomfort during the ECT sessions. The data described, demonstrate that the new permeabilizing protocol adopting biphasic electric pulses displays a significant higher efficacy compared to previous ECT treatments and substantial reduction of the associated morbidity.

Applications of serum protein electrophoresis in exotic pet medicine

Serum Protein Electrophoresis (SPE) is a useful diagnostic and prognostic tool in human and companion animals medicine: several experiences show that it can be useful in exotic practice as well. The fundamentals of SPE interpretation as well as some normal and pathological patterns for the species most commonly seen in practice are provided.

Sexual hormone fluctuation in chinchillas

The data about chinchilla (Chinchilla laniger) reproduction are limited and in some cases discordant. The aim of this study was to monitor the sexual hormone fluctuation by fecal progesterone level and colpocytology analysis by vaginal smears in order to evaluate the different phases of the oestrus cycle. Twenty-four non pregnant chinchillas aged from 1 to 4 years old and subdivided in three groups were monitored. In contrast with findings reported in other study, the high values of progesterone recorded in autumn suggested the presence of a ciclicity also in this period. The data indicate that chinchilla presents a continuous cycle.

Rabbit Clinical Pathology

With rabbit patients, as in other species, analyzing blood and urine samples can be useful and informative, although interpretation of the results is sometimes challenging. This article summarizes the interpretation of laboratory results from rabbits. Hematological parameters can yield information about the red blood cell population and leukocyte response to stress and pathogens. Biochemistry evaluation can be used to investigate liver, kidney, and other organ function, and urinalysis results may yield additional information about kidney function and electrolyte imbalances. Serological tests are available for several pathogens of rabbits, including Encephalitozoon cuniculi, although the significance of positive results and antibody titers is not clear. Serum protein electrophoresis aids the understanding of protein disorders and the immune response to acute and chronic inflammation.

An interesting neurologic case in a lovebird (Agapornis fisheri)

The pathogenic agent of proventricular dilatation disease causes a lymphoplasmacytic inflammation of the central peripheral nervous systems. Usually, the splanchnic nerves are affected, with resultant gastrointestinal dysfunction and clinical signs related to this. When the brain, spinal cord, and peripheral nerves are affected, neurologic signs may be present in various degrees. This case emphasizes the importance of necropsy and histopathologic examination in making a diagnosis and treatment.

Aspirin blocks binding of photosensitizer SnET2 into human serum albumin: implications for photodynamic therapy

Tin etiopurpurin dichloride (SnET2) is one of the photosensitizers under investigation to be used in photodynamic therapy of prostate cancer. The drug is delivered intravenously, transported in vivo by liposomes and plasma proteins and localized within the prostate. SnET2 exists in two tautomeric forms (I - closed ring, II - open ring) with I converting spontaneously into the more energetically stable form II at physiological pH. Up to approximately 50% of the drug can be carried by serum albumin, although this association can increase photo-bleaching and diminish the drug efficiency. Molecular modeling and force field calculations indicate that Sudlow Site I in human serum albumin (HSA) is the most probable binding site for both forms of SnET2, with the porphyrin moiety nestling between domains IIA and IB, and the esterolytic side group oriented toward domain IIIA of HSA. Other drugs, including aspirin, bind to the same part of HSA. SnET2 does not bind to HSA when pre-incubated with aspirin, which confirms that its place of binding to this protein must be located near Lys199. This observation could be exploited to improve photo-efficiency of SnET2 by finding drugs that could compete with the photosensitizer for binding into Sudlow Site I of HSA.

Dosimetric characteristics of a double wall 125I source for interstitial brachytherapy

Recently, a newly designed encapsulated source of 125I has become commercially available for use in permanent and temporary interstitial brachytherapy. The 125I sources in current use come in two different configurations: the Model 6711 source (Medi Physics/Amersham) for permanent implants has radioactive iodine adsorbed on the surface of a silver wire, and the Model 6702 (Medi Physics/Amersham) source for temporary implants has radioactive iodine absorbed in three spherical resin balls. Both of these iodine sources are encapsulated in a thin-walled shell (0.05-mm thick) made of titanium. The newly designed 125I source (Best Industries Model 2300 series) contains radioactive iodine adsorbed on a tungsten wire that is encapsulated by two walls of titanium. This double-walled 125I source offers the following potential advantages: (i) Because it contains radioactive iodine on the ends as well as the circular surface of the tungsten wire, it can produce a more isotropic dose distribution than the sources in current use; (ii) because it is available in a wider range of source strengths, it is suitable for both temporary and permanent implantation; (iii) because it has a tungsten radiographic marker, source localization is considerably easier than the 125I Model 6702 source that has no radiographic marker; and (iv) because it uses a double-walled encapsulation the risk of radioactive contamination due to source rupture is considerably reduced. In this work, dose distributions produced by the new design 125I source (Model 2300) for interstitial brachytherapy have been measured using LiF TLD's in a Solid Water phantom. Dosimetric characteristics of the new 125I sources are compared with those of the currently available 125I sources.(ABSTRACT TRUNCATED AT 250 WORDS)

Anisotropy functions for 103Pd, 125I, and 192Ir interstitial brachytherapy sources

Anisotropy of dose distributions around 103Pd, 125I, and 192Ir sources for interstitial brachytherapy was examined. Dose rates around 125I models 6702 and 6711 and 192Ir sources were measured using lithium fluoride thermoluminescence dosimeters (LiF TLDs) in a water-equivalent, solid phantom. From these measured data for 125I and 192Ir and the previously published measured data for 103Pd, isodose rate contours were determined using a bivariate interpolation and smooth surface fitting algorithm. The anisotropy functions, F(r,theta), as defined by the Interstitial Collaborative Working Group (ICWG) for each source, were determined. Also, 4 pi-averaged anisotropy factors, phi an(r), for use in point source approximation, have been calculated at radial distances varying from 1-10 cm for 103Pd, 125I, and 192Ir sources. The anisotropy factors had average values of 0.90, 0.93, 0.95, and 0.98 for 103Pd, 125I model 6711, 125I model 6702, and 192Ir, respectively. The anisotropy factors determined from dose measurements in phantom are observed to be closer to unity than from those determined previously from in-air measurements. This can be attributed to the smoothing of two-dimensional dose distributions due to the presence of more scattered photons in the phantom measurements compared to in-air measurements. Because in-phantom measurements simulate more closely the brachytherapy patient, data from these experiments are recommended for a more accurate determination of dose distributions around clinical brachytherapy implants. In this work, we present a complete set of source data for two-dimensional dosimetry following the ICWG formalism.

Some treatment planning considerations for 103Pd and 125I permanent interstitial implants

Sealed sources of palladium-103 (103Pd), which decay with a half life of 17 days and emit on average 21 keV photons, are now in clinical use for permanent implants. For seed implantation of prostatic cancer, 103Pd implants are usually planned to deliver 115 Gy to full decay at an initial dose rate of 19.7 cGy/hr whereas 125I implants are usually planned to deliver 160 Gy at an initial dose rate of 7.72 cGy/hr. Because of the lower energy of photons emitted by 103Pd compared to the 125I sources (27 keV average energy), the tissue attenuation is more severe for 103Pd sources. The radial dose function drops more steeply with distance from the 103Pd sources compared to the 125I sources, raising a concern about the possibility of cold spots in the tumors implanted with 103Pd sources. To investigate this issue, a detailed analysis of the dependence of dose uniformity as a function of seed spacing for 125I and 103Pd sources in various cubic and spherical configurations was carried out. Using the measured single source dosimetry data as input, dose distributions for a variety of cubic and spherical implants were generated on a computerized treatment planning system. This study indicates that relative dose distributions for 125I and 103Pd implants with the same geometric configuration and number of seeds are very similar inside the implanted volume for implants. Dose uniformity within a target volume implanted with 103Pd seeds is also very similar to that for 125I. To expedite clinical implementation of 103Pd, an atlas of dose distributions for 103Pd implants has been produced for various seed configurations, seed spacings, and target volumes. Using 125I implants as a guideline, clinical procedures for planning of 103Pd implants have been developed. It was found that the total source strength implanted divided by the dimension of the implant can be expressed as an exponential function of implant size, resulting in a simple method for estimating the strength of seeds necessary in an implant. Also, the air kerma strength of 103Pd seeds is about 3.3 times that of 125I sources in an implant with the same geometric configuration and number of seeds, provided treatment doses of 115 Gy and 160 Gy are chosen for 103Pd and 125I implants, respectively.